What is Abbott Laboratories's earnings per share (EPS)?

Abbott Laboratories (ABT) reported diluted earnings per share of $3.72 for fiscal year 2025. This represents a -51.3% change compared to the previous fiscal year. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.

Abbott Laboratories (ABT) Financials

ABT

Trailing 12 months to March 31, 2026

Revenue $45.1B +6.6% YoY

Net Income $6.3B -53.5% YoY

EPS (Diluted) $3.58 -53.5% YoY

Free Cash Flow $7.4B +10.8% YoY

Market Cap $168.7B as of Oct 2, 2026

Price / Sales 3.7x on $45.1B revenue, trailing 12 months to March 31, 2026

Price / Earnings 26.9x on $6.3B net income, trailing 12 months to March 31, 2026

Price / Book 3.2x on $52.1B equity, Q1 FY2026

A multiple compares the market's price with a filed figure; it says what the market pays, not how the business is doing. The market capitalization is the vendor's as of Oct 2, 2026; every other figure is from the SEC filings on this page. Not financial advice.

Source SEC Filings (10-K/10-Q) Latest period Q1 FY2026, ended Mar 31, 2026 Reported Apr 29, 2026 Currency USD FYE December

Newest figures come from the 10-Q for Q1 FY2026, filed Apr 29, 2026. Each column of the statement tables below links to the filing it was taken from, and every filing is listed on the ABT SEC filings page.

Abbott Laboratories (ABT) reported $45.1B in revenue over the twelve months to Mar 31, 2026, up 6.6% from the prior twelve months. This page shows its income statement, balance sheet, cash flow statement, and key financial ratios. View 15 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Rhea AI ABT FY2025 2026-10-03

Abbott’s cash-generative business shows an operating recovery that matters more than its unusually distorted 2024 net income.

The 2024 net-income surge to $13.4B did not carry into operating cash flow, which was $8.6B, because that year included a $6.4B tax benefit. In 2025, net income normalized to $6.5B while operating cash flow rose to $9.6B, making cash generation a better measure of underlying performance.

From FY2023 to FY2025, operating margin expanded from 16.2% to 18.2%, showing the rebound reached operating profit rather than merely sales. Free-cash-flow margin also rose from 12.6% to 16.7%, indicating more of each sales dollar remained after reinvestment.

Debt-to-equity fell from 0.4x in FY2022 to 0.2x in FY2025, reducing reliance on borrowed capital. Total assets rose from $74.4B to $86.7B while equity expanded, so balance-sheet growth was not accompanied by greater leverage.

Financial Health Signals

Financial Health Score 69/100

Scored against operating companies for FY2025. Each of the six dimensions is a percentile rank within that peer group; the overall is their average, with missing dimensions counted as zero out of six. A high score means strong standing among peers, not absolute cross-industry strength. How this score is calculated →

Health score ≠ stock price. This rates the quality of Abbott Laboratories's business: profitability, growth, balance sheet strength. It doesn't tell you whether the stock is a good buy at today's price. Not financial advice. Use it alongside valuation analysis and your own research.

Profitability

Abbott Laboratories has an operating margin of 18.2%, meaning the company retains $18 of operating profit per $100 of revenue. This strong profitability earns a score of 86/100, reflecting efficient cost management and pricing power. This is up from 16.3% the prior year.

Growth

Abbott Laboratories's revenue grew 5.7% year-over-year to $44.3B, a solid pace of expansion. This earns a growth score of 50/100.

Leverage

Abbott Laboratories carries a low D/E ratio of 0.19, meaning only $0.19 of long-term debt for every $1 of shareholders' equity. This conservative leverage earns a score of 79/100, indicating a strong balance sheet with room for future borrowing.

Liquidity

Abbott Laboratories's current ratio of 1.58 indicates adequate short-term liquidity, earning a score of 44/100. The company can meet its near-term obligations, though with limited headroom.

Cash Flow

Abbott Laboratories converts 16.7% of revenue into free cash flow ($7.4B). This strong cash generation earns a score of 79/100.

Returns

Abbott Laboratories earns a strong 12.5% return on equity (ROE), meaning it generates $13 of profit for every $100 of shareholders' equity. This efficient capital use earns a returns score of 76/100. This is down from 28.1% the prior year.

Altman Z-Score Safe

4.68

Abbott Laboratories scores 4.68, well above the 2.99 safe threshold. The score is driven primarily by a large market capitalization ($168.7B) relative to total liabilities ($34.6B). This indicates low bankruptcy risk based on profitability, leverage, and asset efficiency.

Distress-screening estimate for non-financial companies. Not computed for banks or insurers, where the Altman model does not apply.

Piotroski F-Score Neutral

5/9

Abbott Laboratories passes 5 of 9 financial strength tests. 3 of 4 profitability signals pass, 1 of 3 leverage/liquidity signals pass, 1 of 2 efficiency signals pass.

Earnings Quality Cash-Backed

1.47x

For every $1 of reported earnings, Abbott Laboratories generates $1.47 in operating cash flow ($9.6B OCF vs $6.5B net income). This indicates profits are well-supported by actual cash generation, not accounting adjustments.

Interest Coverage Safe

16.33x

Abbott Laboratories earns $16.33 in operating income for every $1 of interest expense ($8.1B vs $493.0M). This wide margin provides strong safety for debt servicing, even if earnings decline temporarily.

Key Financial Metrics

Export CSV

Earnings & Revenue

Revenue

$11.2B

YoY+7.8%

QoQ-2.6%

5Y CAGR+1.3%

10Y CAGR+8.6%

Abbott Laboratories generated $11.2B in revenue in Q1 2026. This represents an increase of 7.8% from the same quarter a year earlier. Against the prior quarter it is down 2.6%.

EBITDA

$2.1B

YoY-12.3%

QoQ-29.4%

5Y CAGR-6.7%

Abbott Laboratories's EBITDA was $2.1B in Q1 2026, measuring earnings before interest, taxes, depreciation, and amortization. This represents a decrease of 12.3% from the same quarter a year earlier. Against the prior quarter it is down 29.4%.

Net Income

$1.1B

YoY-18.7%

QoQ-39.4%

5Y CAGR-9.7%

10Y CAGR+13.0%

Abbott Laboratories reported $1.1B in net income in Q1 2026. This represents a decrease of 18.7% from the same quarter a year earlier. Against the prior quarter it is down 39.4%.

EPS (Diluted)

$0.61

YoY-19.7%

QoQ-40.2%

5Y CAGR-9.4%

10Y CAGR+11.3%

Abbott Laboratories earned $0.61 per diluted share (EPS) in Q1 2026. This represents a decrease of 19.7% from the same quarter a year earlier. Against the prior quarter it is down 40.2%.

Cash & Balance Sheet

Free Cash Flow

$916.0M

YoY-1.8%

QoQ-65.1%

5Y CAGR-16.4%

Abbott Laboratories generated $916.0M in free cash flow in Q1 2026, representing cash available after capex. This represents a decrease of 1.8% from the same quarter a year earlier. Against the prior quarter it is down 65.1%.

Cash & Debt

$6.8B

YoY+4.1%

QoQ-20.2%

5Y CAGR-3.3%

10Y CAGR+7.4%

Abbott Laboratories held $6.8B in cash against $29.6B in long-term debt as of Q1 2026.

Dividends Per Share

$0.63

YoY+6.8%

QoQ0.0%

Abbott Laboratories paid $0.63 per share in dividends in Q1 2026. This represents an increase of 6.8% from the same quarter a year earlier. It is unchanged from the prior quarter.

Shares Outstanding

1.74B

YoY+0.1%

QoQ+0.2%

5Y CAGR-0.4%

10Y CAGR+1.7%

Abbott Laboratories had 1.74B shares outstanding in Q1 2026. This represents an increase of 0.1% from the same quarter a year earlier. Against the prior quarter it is up 0.2%.

Margins & Returns

Gross Margin

56.2%

YoY-0.7pp

QoQ-0.8pp

5Y change-1.7pp

10Y change+3.0pp

Abbott Laboratories's gross margin was 56.2% in Q1 2026, indicating the percentage of revenue retained after direct costs. This is down 0.7 percentage points from the same quarter a year earlier. Against the prior quarter it is down 0.8 percentage points.

Operating Margin

12.0%

YoY-4.3pp

QoQ-7.6pp

5Y change-8.1pp

Abbott Laboratories's operating margin was 12.0% in Q1 2026, reflecting core business profitability. This is down 4.3 percentage points from the same quarter a year earlier. Against the prior quarter it is down 7.6 percentage points.

Net Margin

9.7%

YoY-3.1pp

QoQ-5.8pp

5Y change-7.5pp

10Y change+3.2pp

Abbott Laboratories's net profit margin was 9.7% in Q1 2026, showing the share of revenue converted to profit. This is down 3.1 percentage points from the same quarter a year earlier. Against the prior quarter it is down 5.8 percentage points.

Return on Equity

2.1%

YoY-0.6pp

QoQ-1.3pp

5Y change-3.3pp

10Y change+0.5pp

Abbott Laboratories's ROE was 2.1% in Q1 2026, measuring profit generated per dollar of shareholder equity. This is down 0.6 percentage points from the same quarter a year earlier. Against the prior quarter it is down 1.3 percentage points.

Capital Allocation

R&D Spending

$767.0M

YoY+7.1%

QoQ+4.4%

5Y CAGR+3.2%

Abbott Laboratories invested $767.0M in research and development in Q1 2026. This represents an increase of 7.1% from the same quarter a year earlier. Against the prior quarter it is up 4.4%.

Share Buybacks

$180.0M

YoY-35.7%

QoQ-40.4%

5Y CAGR-8.1%

10Y CAGR-10.0%

Abbott Laboratories spent $180.0M on share buybacks in Q1 2026, returning capital to shareholders by reducing shares outstanding. This represents a decrease of 35.7% from the same quarter a year earlier. Against the prior quarter it is down 40.4%.

Capital Expenditures

$399.0M

YoY-17.6%

QoQ-42.1%

5Y CAGR+0.1%

10Y CAGR+5.1%

Abbott Laboratories invested $399.0M in capex in Q1 2026, funding long-term assets and infrastructure. This represents a decrease of 17.6% from the same quarter a year earlier. Against the prior quarter it is down 42.1%.

ABT Income Statement

Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

ABT quarterly income statement

Metric	TTM	FY2510-K	FY2410-K	FY2310-K	FY2210-K	FY2110-K	FY2010-K	FY1910-K	FY1810-K	FY1710-K	FY1610-K	FY1510-K	FY1410-K	FY1310-K	FY1210-K	FY1110-K
Revenue	$45.1B	$44.3B+5.7%	$42.0B+4.6%	$40.1B-8.1%	$43.7B+1.3%	$43.1B+24.5%	$34.6B+8.5%	$31.9B+4.3%	$30.6B+11.6%	$27.4B+31.3%	$20.9B+2.2%	$20.4B+0.8%	$20.2B+3.0%	$19.7B+3.2%	$19.1B-11.0%	$21.4B
Cost of Revenue	$19.7B	$19.3B+3.3%	$18.7B+4.1%	$18.0B-6.1%	$19.1B+3.3%	$18.5B+23.6%	$15.0B+13.4%	$13.2B+4.1%	$12.7B+2.4%	$12.4B+36.5%	$9.1B+4.0%	$8.7B-5.1%	$9.2B+0.3%	$9.2B+3.3%	$8.9B-11.2%	$10.0B
Gross Profit	$25.4B	$25.0B+7.6%	$23.2B+5.0%	$22.1B-9.7%	$24.5B-0.1%	$24.5B+25.2%	$19.6B+5.0%	$18.7B+4.5%	$17.9B+19.3%	$15.0B+27.4%	$11.8B+0.9%	$11.7B+5.7%	$11.0B+5.4%	$10.5B+3.1%	$10.2B-10.9%	$11.4B
R&D Expenses	$3.0B	$2.9B+3.4%	$2.8B+3.8%	$2.7B-5.1%	$2.9B+5.3%	$2.7B+13.3%	$2.4B-0.8%	$2.4B+6.1%	$2.3B+1.8%	$2.3B+56.2%	$1.4B+3.0%	$1.4B+4.5%	$1.3B-1.9%	$1.4B-6.2%	$1.5B-3.4%	$1.5B
SG&A Expenses	$13.0B	$12.3B+5.4%	$11.7B+6.8%	$10.9B-2.7%	$11.2B-0.7%	$11.3B+16.8%	$9.7B-0.7%	$9.8B+0.2%	$9.7B+6.1%	$9.2B+36.3%	$6.7B-0.7%	$6.8B+3.9%	$6.5B+2.5%	$6.4B-5.4%	$6.7B-8.6%	$7.4B
Operating Income	$7.7B	$8.1B+18.0%	$6.8B+5.4%	$6.5B-22.5%	$8.4B-0.7%	$8.4B+57.3%	$5.4B+18.2%	$4.5B+24.2%	$3.6B+133.4%	$1.6B-48.3%	$3.0B+5.5%	$2.9B+10.3%	$2.6B+21.8%	$2.1B+56.8%	$1.4B-16.5%	$1.6B
EBITDA	N/A	$11.2B+11.2%	$10.0B+3.3%	$9.7B-16.4%	$11.6B-2.8%	$12.0B+37.8%	$8.7B+15.1%	$7.5B+8.9%	$6.9B+51.1%	$4.6B+4.7%	$4.4B+0.9%	$4.3B+4.6%	$4.1B+7.7%	$3.9B-7.0%	$4.1B-11.4%	$4.7B
Interest Expense	$536.0M	$493.0M-11.8%	$559.0M-12.2%	$637.0M+14.2%	$558.0M+4.7%	$533.0M-2.4%	$546.0M-18.5%	$670.0M-18.9%	$826.0M-8.6%	$904.0M+109.7%	$431.0M+164.4%	$163.0M+8.7%	$150.0M+3.4%	$145.0M-54.7%	$320.0M-10.9%	$359.0M
Income Tax	$1.9B	$1.9B+130.4%	-$6.4B-779.0%	$941.0M-31.5%	$1.4B+20.4%	$1.1B+129.4%	$497.0M+27.4%	$390.0M-27.6%	$539.0M-71.3%	$1.9B+436.6%	$350.0M-39.3%	$577.0M-27.6%	$797.0M+1403.8%	$53.0M+111.6%	-$457.0M-515.5%	$110.0M
Net Income	$6.3B	$6.5B-51.3%	$13.4B+134.2%	$5.7B-17.5%	$6.9B-2.0%	$7.1B+57.3%	$4.5B+21.9%	$3.7B+55.7%	$2.4B+396.4%	$477.0M-65.9%	$1.4B-68.3%	$4.4B+93.7%	$2.3B-11.3%	$2.6B-56.8%	$6.0B+26.1%	$4.7B
EPS (Basic)	N/A	$3.73-51.4%	$7.67+133.8%	$3.28-16.8%	$3.94-0.8%	$3.97+57.5%	$2.52+21.7%	$2.07+54.5%	$1.34+396.3%	$0.27-71.3%	$0.94-68.0%	$2.94+96.0%	$1.50-8.5%	$1.64-56.4%	$3.76+24.1%	$3.03
EPS (Diluted)	$3.58	$3.72-51.3%	$7.64+134.4%	$3.26-16.6%	$3.91-0.8%	$3.94+57.6%	$2.50+21.4%	$2.06+54.9%	$1.33+392.6%	$0.27-71.3%	$0.94-67.8%	$2.92+96.0%	$1.49-8.0%	$1.62-56.5%	$3.72+23.6%	$3.01
Diluted Shares (Avg)	N/A	1.75B0.0%	1.75B-0.1%	1.75B-0.9%	1.76B-1.4%	1.79B+0.2%	1.79B+0.3%	1.78B+0.6%	1.77B+1.2%	1.75B+17.9%	1.48B-1.5%	1.51B-1.4%	1.53B-3.0%	1.57B-1.1%	1.59B+1.6%	1.57B

Metric	Q1'2610-Q	Q4'2510-Q	Q3'2510-Q	Q2'2510-Q	Q1'2510-Q	Q4'2410-K	Q3'2410-Q	Q2'2410-Q
Revenue	$11.2B+7.8%	$11.5B+4.4%	$11.4B+6.9%	$11.1B+7.4%	$10.4B+4.0%	$11.0B+7.2%	$10.6B+4.9%	$10.4B+4.0%
Cost of Revenue	$4.9B+9.4%	$4.9B-0.4%	$5.1B+8.0%	$4.9B+5.5%	$4.5B+0.1%	$4.9B+8.5%	$4.7B+2.0%	$4.6B+2.7%
Gross Profit	$6.3B+6.5%	$6.5B+8.4%	$6.3B+6.0%	$6.3B+8.9%	$5.9B+7.1%	$6.0B+6.1%	$5.9B+7.2%	$5.8B+5.1%
R&D Expenses	$767.0M+7.1%	$735.0M-1.9%	$766.0M+7.4%	$725.0M+3.9%	$716.0M+4.7%	$749.0M+7.0%	$713.0M+6.1%	$698.0M-2.4%
SG&A Expenses	$3.7B+22.2%	$3.1B+7.6%	$3.1B+5.4%	$3.1B+5.3%	$3.1B+3.4%	$2.9B+6.7%	$2.9B+6.3%	$2.9B+7.2%
Operating Income	$1.3B-20.6%	$2.3B+17.8%	$2.1B+10.7%	$2.1B+22.9%	$1.7B+22.2%	$1.9B+7.4%	$1.9B+12.9%	$1.7B+8.2%
EBITDA	$2.1B-12.3%	$3.0B+12.0%	$2.8B+7.1%	$2.8B+14.3%	$2.4B+11.8%	$2.7B+4.8%	$2.7B+7.6%	$2.5B+5.6%
Interest Expense	$174.0M+32.8%	$120.0M-11.8%	$121.0M-14.8%	$121.0M-13.6%	$131.0M-7.1%	$136.0M-14.5%	$142.0M-14.5%	$140.0M-11.9%
Income Tax	$372.0M-17.9%	$582.0M+108.1%	$536.0M+82.3%	$371.0M+21.6%	$453.0M+114.7%	-$7.2B-3681.6%	$294.0M+25.1%	$305.0M+16.9%
Net Income	$1.1B-18.7%	$1.8B-80.8%	$1.6B-0.1%	$1.8B+36.6%	$1.3B+8.2%	$9.2B+479.0%	$1.6B+14.6%	$1.3B-5.3%
EPS (Basic)	$0.62-18.4%	$1.01-80.9%	$0.940.0%	$1.02+37.8%	$0.76+8.6%	$5.28+473.9%	$0.94+14.6%	$0.74-6.3%
EPS (Diluted)	$0.61-19.7%	$1.02-80.6%	$0.940.0%	$1.01+36.5%	$0.76+8.6%	$5.26+478.0%	$0.94+14.6%	$0.74-5.1%
Diluted Shares (Avg)	1.75B0.0%	N/A	1.75B+0.1%	1.75B0.0%	1.75B-0.1%	N/A	1.75B0.0%	1.75B+0.1%

ABT Balance Sheet

ABT quarterly balance sheet

Metric	FY2510-K	FY2410-K	FY2310-K	FY2210-K	FY2110-K	FY2010-K	FY1910-K	FY1810-K	FY1710-K	FY1610-K	FY1510-K	FY1410-K	FY1310-K	FY1210-K	FY1110-K
Total Assets	$86.7B+6.5%	$81.4B+11.2%	$73.2B-1.6%	$74.4B-1.0%	$75.2B+3.6%	$72.5B+6.9%	$67.9B+1.1%	$67.2B-11.9%	$76.3B+44.8%	$52.7B+27.7%	$41.2B+0.1%	$41.2B-4.0%	$42.9B-36.1%	$67.2B+11.5%	$60.3B
Current Assets	$26.0B+9.9%	$23.7B+4.3%	$22.7B-10.1%	$25.2B+4.1%	$24.2B+18.6%	$20.4B+30.5%	$15.7B+7.1%	$14.6B-27.4%	$20.1B-24.8%	$26.8B+89.2%	$14.2B+4.4%	$13.6B-29.6%	$19.2B-38.6%	$31.3B+31.8%	$23.8B
Cash & Equivalents	$8.5B+11.9%	$7.6B+10.4%	$6.9B-30.2%	$9.9B+0.8%	$9.8B+43.3%	$6.8B+77.2%	$3.9B+0.4%	$3.8B-59.1%	$9.4B-49.5%	$18.6B+272.3%	$5.0B+23.1%	$4.1B+16.9%	$3.5B-67.8%	$10.8B+58.5%	$6.8B
Short-Term Investments	$417.0M+18.8%	$351.0M-8.4%	$383.0M+33.0%	$288.0M-36.0%	$450.0M+45.2%	$310.0M+10.7%	$280.0M+15.7%	$242.0M+19.2%	$203.0M+31.0%	$155.0M-86.2%	$1.1B+183.1%	$397.0M-91.4%	$4.6B+5.7%	$4.4B+240.4%	$1.3B
Inventory	$6.5B+4.7%	$6.2B-5.7%	$6.6B+6.4%	$6.2B+19.7%	$5.2B+2.9%	$5.0B+16.1%	$4.3B+13.7%	$3.8B+5.4%	$3.6B+47.9%	$2.4B-6.3%	$2.6B-1.7%	$2.6B-1.9%	$2.7B-29.0%	$3.8B+15.5%	$3.3B
Accounts Receivable	$7.9B+14.5%	$6.9B+5.5%	$6.6B+5.6%	$6.2B-4.1%	$6.5B+1.1%	$6.4B+18.2%	$5.4B+4.7%	$5.2B-1.3%	$5.2B+61.6%	$3.2B-5.0%	$3.4B-4.7%	$3.6B-10.0%	$4.0B-47.6%	$7.6B-0.9%	$7.7B
Long-Term Investments	$918.0M+3.6%	$886.0M+10.9%	$799.0M+4.3%	$766.0M-6.1%	$816.0M-0.6%	$821.0M-7.0%	$883.0M-1.6%	$897.0M+1.6%	$883.0M-70.0%	$2.9B-27.1%	$4.0B+1664.6%	$229.0M+92.4%	$119.0M-56.6%	$274.0M-27.6%	$378.2M
Goodwill	$24.0B+4.0%	$23.1B-2.4%	$23.7B+3.9%	$22.8B-1.9%	$23.2B-2.2%	$23.7B+2.4%	$23.2B-0.3%	$23.3B-3.2%	$24.0B+212.6%	$7.7B-20.3%	$9.6B-4.3%	$10.1B+3.0%	$9.8B-38.0%	$15.8B+0.4%	$15.7B
Total Liabilities	$34.6B+2.5%	$33.8B-2.5%	$34.6B-8.3%	$37.8B-4.2%	$39.4B-0.9%	$39.8B+8.1%	$36.8B+0.4%	$36.6B-19.2%	$45.4B+41.2%	$32.1B+60.4%	$20.0B+1.8%	$19.7B+10.8%	$17.8B-56.1%	$40.5B+13.1%	$35.8B
Current Liabilities	$16.5B+16.5%	$14.2B+2.3%	$13.8B-10.6%	$15.5B+18.2%	$13.1B+10.1%	$11.9B+9.6%	$10.9B+20.5%	$9.0B+1.1%	$8.9B+33.8%	$6.7B-27.5%	$9.2B-12.2%	$10.5B+10.1%	$9.5B-28.4%	$13.3B-14.2%	$15.5B
Non-Current Liabilities	$18.1B-7.7%	$19.6B-5.7%	$20.8B-6.7%	$22.3B-15.3%	$26.3B-5.6%	$27.9B+7.4%	$25.9B-6.2%	$27.6B-24.2%	$36.4B+43.1%	$25.5B+134.7%	$10.8B+17.8%	$9.2B+11.6%	$8.3B-69.7%	$27.2B+33.8%	$20.4B
Long-Term Debt	$9.9B-21.6%	$12.6B-7.2%	$13.6B-6.4%	$14.5B-16.0%	$17.3B-6.6%	$18.5B+11.2%	$16.7B-13.9%	$19.4B-28.9%	$27.2B+31.6%	$20.7B+252.3%	$5.9B+73.0%	$3.4B+0.1%	$3.4B-81.3%	$18.1B+50.2%	$12.0B
Total Equity	$52.1B+9.4%	$47.7B+23.5%	$38.6B+5.2%	$36.7B+2.5%	$35.8B+9.2%	$32.8B+5.5%	$31.1B+1.8%	$30.5B-1.2%	$30.9B+50.4%	$20.5B-3.2%	$21.2B-1.5%	$21.5B-14.5%	$25.2B-5.8%	$26.7B+9.3%	$24.4B
Retained Earnings	$49.8B+5.3%	$47.3B+25.8%	$37.6B+6.5%	$35.3B+11.8%	$31.5B+14.1%	$27.6B+6.9%	$25.8B+5.2%	$24.6B+2.4%	$24.0B-6.2%	$25.6B-0.7%	$25.8B+12.6%	$22.9B+4.1%	$22.0B-9.0%	$24.2B+15.5%	$20.9B

Metric	Q1'2610-Q	Q4'2510-Q	Q3'2510-Q	Q2'2510-Q	Q1'2510-Q	Q4'2410-K	Q3'2410-Q	Q2'2410-Q
Total Assets	$110.4B+35.6%	$86.7B+6.5%	$84.2B+13.2%	$84.0B+15.0%	$81.4B+12.4%	$81.4B+11.2%	$74.4B+3.1%	$73.0B-0.5%
Current Assets	$25.5B+10.2%	$26.0B+9.9%	$24.8B+4.4%	$24.5B+5.8%	$23.2B+3.5%	$23.7B+4.3%	$23.8B+5.0%	$23.1B-1.6%
Cash & Equivalents	$6.8B+4.1%	$8.5B+11.9%	$7.5B-0.6%	$7.0B-0.5%	$6.5B+3.9%	$7.6B+10.4%	$7.6B+12.7%	$7.0B-10.8%
Short-Term Investments	$492.0M+57.7%	$417.0M+18.8%	$222.0M-3.5%	$331.0M+42.7%	$312.0M-15.0%	$351.0M-8.4%	$230.0M-32.0%	$232.0M-27.5%
Inventory	$7.0B+5.3%	$6.5B+4.7%	$6.7B-1.5%	$7.0B+2.1%	$6.6B-2.8%	$6.2B-5.7%	$6.8B+2.5%	$6.8B-0.8%
Accounts Receivable	$8.2B+12.1%	$7.9B+14.5%	$8.1B+15.4%	$8.0B+16.3%	$7.3B+10.9%	$6.9B+5.5%	$7.1B+8.5%	$6.9B+11.0%
Long-Term Investments	$1.1B+20.2%	$918.0M+3.6%	$951.0M+4.3%	$958.0M+9.2%	$907.0M+10.9%	$886.0M+10.9%	$912.0M+15.7%	$877.0M+9.8%
Goodwill	$35.2B+50.8%	$24.0B+4.0%	$24.0B+1.3%	$24.0B+2.8%	$23.4B-0.1%	$23.1B-2.4%	$23.7B+1.6%	$23.3B+0.2%
Total Liabilities	$58.4B+78.8%	$34.6B+2.5%	$33.2B-3.9%	$33.4B-0.8%	$32.6B-3.0%	$33.8B-2.5%	$34.6B-0.1%	$33.7B-6.9%
Current Liabilities	$18.4B+41.3%	$16.5B+16.5%	$14.6B-2.1%	$13.4B-2.3%	$13.0B-7.3%	$14.2B+2.3%	$14.9B+14.3%	$13.8B-4.1%
Non-Current Liabilities	$40.0B+103.7%	$18.1B-7.7%	$18.6B-5.2%	$20.0B+0.3%	$19.6B0.0%	$19.6B-5.7%	$19.7B-8.9%	$19.9B-8.7%
Long-Term Debt	$29.6B+132.7%	$9.9B-21.6%	$11.6B-9.6%	$12.9B-1.6%	$12.7B+1.3%	$12.6B-7.2%	$12.8B-11.4%	$13.1B-9.8%
Total Equity	$52.1B+6.7%	$52.1B+9.4%	$51.0B+28.0%	$50.6B+28.6%	$48.8B+25.8%	$47.7B+23.5%	$39.8B+6.2%	$39.3B+5.8%
Retained Earnings	$50.0B+4.7%	$49.8B+5.3%	$49.1B+25.7%	$48.5B+26.4%	$47.7B+25.5%	$47.3B+25.8%	$39.1B+5.8%	$38.4B+5.5%

ABT Cash Flow Statement

ABT quarterly cash flow statement

Metric	TTM	FY2510-K	FY2410-K	FY2310-K	FY2210-K	FY2110-K	FY2010-K	FY1910-K	FY1810-K	FY1710-K	FY1610-K	FY1510-K	FY1410-K	FY1310-K	FY1210-K	FY1110-K
Operating Cash Flow	$9.5B	$9.6B+11.8%	$8.6B+17.9%	$7.3B-24.2%	$9.6B-9.0%	$10.5B+33.3%	$7.9B+28.8%	$6.1B-2.6%	$6.3B+13.1%	$5.6B+73.9%	$3.2B+8.0%	$3.0B-19.3%	$3.7B+10.6%	$3.3B-64.3%	$9.3B+3.8%	$9.0B
Depreciation & Amortization	N/A	$3.1B-3.2%	$3.2B-0.8%	$3.2B-0.7%	$3.3B-7.7%	$3.5B+6.3%	$3.3B+10.4%	$3.0B-8.1%	$3.3B+8.5%	$3.0B+123.3%	$1.4B-8.1%	$1.5B-4.9%	$1.5B-9.9%	$1.7B-38.2%	$2.8B-8.6%	$3.0B
Stock-Based Compensation	N/A	$664.0M-1.3%	$673.0M+4.5%	$644.0M-6.0%	$685.0M+7.0%	$640.0M+17.2%	$546.0M+5.2%	$519.0M+8.8%	$477.0M+17.5%	$406.0M+31.0%	$310.0M+6.2%	$292.0M+18.7%	$246.0M-6.1%	$262.0M-39.5%	$433.0M+13.1%	$383.0M
Capital Expenditures	$2.1B	$2.2B-1.6%	$2.2B+0.2%	$2.2B+23.9%	$1.8B-5.7%	$1.9B-13.4%	$2.2B+32.9%	$1.6B+17.5%	$1.4B+22.8%	$1.1B+1.2%	$1.1B+1.0%	$1.1B+3.1%	$1.1B-5.9%	$1.1B-36.2%	$1.8B+20.4%	$1.5B
Free Cash Flow	$7.4B	$7.4B+16.4%	$6.4B+25.5%	$5.1B-35.2%	$7.8B-9.8%	$8.6B+51.1%	$5.7B+27.3%	$4.5B-8.3%	$4.9B+10.6%	$4.4B+113.0%	$2.1B+12.2%	$1.9B-28.6%	$2.6B+19.2%	$2.2B-71.0%	$7.5B+0.5%	$7.5B
Investing Cash Flow	-$22.3B	-$2.4B-3.6%	-$2.3B+25.4%	-$3.1B-80.1%	-$1.7B+13.3%	-$2.0B+9.3%	-$2.2B-22.0%	-$1.8B-33.8%	-$1.4B+85.9%	-$9.6B-3778.2%	-$248.0M-161.1%	$406.0M+301.0%	-$202.0M+94.9%	-$3.9B+29.3%	-$5.6B-941.1%	$661.0M
Financing Cash Flow	$13.1B	-$6.3B-16.7%	-$5.4B+23.8%	-$7.1B+7.1%	-$7.6B-39.0%	-$5.5B-97.7%	-$2.8B+35.2%	-$4.3B+58.7%	-$10.4B-96.8%	-$5.3B-147.4%	$11.1B+598.5%	-$2.2B+18.5%	-$2.7B+59.1%	-$6.7B-3533.8%	$195.0M+103.0%	-$6.4B
Dividends Paid	$4.2B	$4.1B+7.3%	$3.8B+7.9%	$3.6B+7.5%	$3.3B+3.3%	$3.2B+25.1%	$2.6B+12.8%	$2.3B+15.0%	$2.0B+6.8%	$1.8B+20.1%	$1.5B+6.7%	$1.4B+7.5%	$1.3B+52.2%	$882.0M-72.3%	$3.2B+8.3%	$2.9B
Share Buybacks	$793.0M	$893.0M-31.0%	$1.3B+5.5%	$1.2B-67.7%	$3.8B+65.1%	$2.3B+470.5%	$403.0M-43.9%	$718.0M+201.7%	$238.0M+103.4%	$117.0M-77.6%	$522.0M-76.7%	$2.2B+1.9%	$2.2B+36.8%	$1.6B-32.1%	$2.4B+2970.1%	$77.0M

Metric	Q1'2610-Q	Q4'2510-Q	Q3'2510-Q	Q2'2510-Q	Q1'2510-Q	Q4'2410-K	Q3'2410-Q	Q2'2410-Q
Operating Cash Flow	$1.3B-7.2%	$3.3B+15.6%	$2.8B+3.0%	$2.0B+4.4%	$1.4B+38.2%	$2.9B-5.6%	$2.7B+44.1%	$2.0B+62.9%
Depreciation & Amortization	$803.0M+6.2%	$792.0M-1.9%	$791.0M-1.2%	$777.0M-3.5%	$756.0M-6.1%	$807.0M-0.7%	$801.0M-2.8%	$805.0M+0.6%
Stock-Based Compensation	$317.0M+9.7%	N/A	N/A	N/A	$289.0M-4.9%	N/A	N/A	N/A
Capital Expenditures	$399.0M-17.6%	$689.0M-4.3%	$496.0M-10.8%	$502.0M-5.8%	$484.0M+21.6%	$720.0M-4.6%	$556.0M-0.7%	$533.0M+5.1%
Free Cash Flow	$916.0M-1.8%	$2.6B+22.3%	$2.3B+6.6%	$1.5B+8.3%	$933.0M+48.8%	$2.1B-5.9%	$2.1B+63.2%	$1.4B+105.0%
Investing Cash Flow	-$20.3B-4224.3%	-$913.0M-5.4%	-$457.0M+23.1%	-$582.0M-28.5%	-$470.0M-10.6%	-$866.0M-5.1%	-$594.0M+6.3%	-$453.0M+62.7%
Financing Cash Flow	$17.3B+942.5%	-$1.4B+24.9%	-$1.8B-11.7%	-$1.1B-38.7%	-$2.1B-74.7%	-$1.9B+9.3%	-$1.6B+32.6%	-$791.0M+38.6%
Dividends Paid	$1.1B+7.0%	$1.0B+7.5%	$1.0B+7.4%	$1.0B+7.1%	$1.0B+7.2%	$958.0M+7.9%	$960.0M+8.1%	$961.0M+8.0%
Share Buybacks	$180.0M-35.7%	$302.0M-4.1%	$305.0M-59.4%	$6.0M+100.0%	$280.0M+23.9%	$315.0M+21.6%	$751.0M+37450.0%	$3.0M-99.3%

ABT Financial Ratios

Margins and returns are percentages; the remaining ratios are unitless multiples. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

ABT quarterly financial ratios

Metric	FY2510-K	FY2410-K	FY2310-K	FY2210-K	FY2110-K	FY2010-K	FY1910-K	FY1810-K	FY1710-K	FY1610-K	FY1510-K	FY1410-K	FY1310-K	FY1210-K	FY1110-K
Gross Margin	56.4%+1.0pp	55.4%+0.2pp	55.2%-1.0pp	56.1%-0.8pp	57.0%+0.3pp	56.6%-1.9pp	58.5%+0.1pp	58.5%+3.7pp	54.7%-1.7pp	56.4%-0.7pp	57.1%+2.7pp	54.5%+1.2pp	53.2%-0.1pp	53.3%+0.1pp	53.2%
Operating Margin	18.2%+1.9pp	16.3%+0.1pp	16.2%-3.0pp	19.2%-0.4pp	19.6%+4.1pp	15.5%+1.3pp	14.2%+2.3pp	11.9%+6.2pp	5.7%-8.8pp	14.5%+0.5pp	14.1%+1.2pp	12.8%+2.0pp	10.8%+3.7pp	7.1%-0.5pp	7.6%
Net Margin	14.7%-17.2pp	31.9%+17.7pp	14.3%-1.6pp	15.9%-0.5pp	16.4%+3.4pp	13.0%+1.4pp	11.6%+3.8pp	7.7%+6.0pp	1.7%-5.0pp	6.7%-15.0pp	21.7%+10.4pp	11.3%-1.8pp	13.1%-18.2pp	31.3%+9.2pp	22.1%
Return on Equity	12.5%-15.6pp	28.1%+13.3pp	14.8%-4.1pp	18.9%-0.9pp	19.8%+6.0pp	13.7%+1.9pp	11.9%+4.1pp	7.8%+6.2pp	1.5%-5.3pp	6.8%-14.0pp	20.8%+10.2pp	10.6%+0.4pp	10.2%-12.1pp	22.3%+3.0pp	19.4%
Return on Assets	7.5%-8.9pp	16.5%+8.6pp	7.8%-1.5pp	9.3%-0.1pp	9.4%+3.2pp	6.2%+0.8pp	5.4%+1.9pp	3.5%+2.9pp	0.6%-2.0pp	2.7%-8.1pp	10.7%+5.2pp	5.5%-0.5pp	6.0%-2.9pp	8.9%+1.0pp	7.8%
Current Ratio	1.58-0.1x	1.670.0x	1.640.0x	1.63-0.2x	1.85+0.1x	1.72+0.3x	1.44-0.2x	1.62-0.6x	2.26-1.8x	4.02+2.5x	1.54+0.2x	1.30-0.7x	2.02-0.3x	2.36+0.8x	1.54
Debt-to-Equity	0.19-0.1x	0.26-0.1x	0.350.0x	0.40-0.1x	0.48-0.1x	0.570.0x	0.54-0.1x	0.63-0.2x	0.88-0.1x	1.01+0.7x	0.28+0.1x	0.160.0x	0.13-0.5x	0.68+0.2x	0.49
Asset Turnover	0.510.0x	0.520.0x	0.550.0x	0.590.0x	0.57+0.1x	0.480.0x	0.470.0x	0.46+0.1x	0.360.0x	0.40-0.1x	0.490.0x	0.490.0x	0.46+0.2x	0.28-0.1x	0.36
FCF Margin	16.7%+1.5pp	15.1%+2.5pp	12.6%-5.3pp	17.9%-2.2pp	20.1%+3.5pp	16.5%+2.4pp	14.1%-1.9pp	16.0%-0.2pp	16.2%+6.2pp	10.0%+0.9pp	9.1%-3.7pp	12.8%+1.7pp	11.1%-28.4pp	39.5%+4.5pp	34.9%

Metric	Q1'2610-Q	Q4'2510-Q	Q3'2510-Q	Q2'2510-Q	Q1'2510-Q	Q4'2410-K	Q3'2410-Q	Q2'2410-Q
Gross Margin	56.2%-0.7pp	57.0%+2.1pp	55.4%-0.5pp	56.4%+0.8pp	56.9%+1.6pp	55.0%-0.5pp	55.8%+1.2pp	55.6%+0.6pp
Operating Margin	12.0%-4.3pp	19.6%+2.2pp	18.1%+0.6pp	18.4%+2.3pp	16.3%+2.4pp	17.4%0.0pp	17.5%+1.2pp	16.1%+0.6pp
Net Margin	9.7%-3.1pp	15.5%-68.6pp	14.5%-1.0pp	16.0%+3.4pp	12.8%+0.5pp	84.1%+68.5pp	15.5%+1.3pp	12.6%-1.2pp
Return on Equity	2.1%-0.6pp	3.4%-16.0pp	3.2%-0.9pp	3.5%+0.2pp	2.7%-0.5pp	19.4%+15.2pp	4.1%+0.3pp	3.3%-0.4pp
Return on Assets	1.0%-0.6pp	2.1%-9.3pp	1.9%-0.3pp	2.1%+0.3pp	1.6%-0.1pp	11.3%+9.2pp	2.2%+0.2pp	1.8%-0.1pp
Current Ratio	1.39-0.4x	1.58-0.1x	1.70+0.1x	1.82+0.1x	1.78+0.2x	1.670.0x	1.60-0.1x	1.680.0x
Debt-to-Equity	0.57+0.3x	0.19-0.1x	0.23-0.1x	0.26-0.1x	0.26-0.1x	0.26-0.1x	0.32-0.1x	0.33-0.1x
Asset Turnover	0.100.0x	0.130.0x	0.140.0x	0.130.0x	0.130.0x	0.130.0x	0.140.0x	0.140.0x
FCF Margin	8.2%-0.8pp	22.9%+3.3pp	20.2%-0.1pp	13.9%+0.1pp	9.0%+2.7pp	19.6%-2.7pp	20.2%+7.2pp	13.8%+6.8pp

Similar Companies

Newest fiscal year on record for each company. The health score is the peer-relative Financial Health Score for that year; a dash means no score is published for it.

Company	Fiscal year	Revenue	Net income	Net margin	Market cap	Health score
Abbott Laboratories ABT	FY2025	$44.3B	$6.5B	14.7%	$168.7B	69/100
Boston Scientific Corporation BSX	FY2025	$20.1B	$2.9B	14.4%	$61.7B	65/100
Stryker Corporation SYK	FY2025	$25.1B	$3.2B	12.9%	$105.6B	67/100
Medtronic plc MDT	FY2026	$36.4B	$5K	0.0%	$110.5B	63/100
Edwards Lifesciences Corp EW	FY2025	$6.1B	$1.1B	17.7%	$49.1B	73/100
Smith & Nephew plc SNN	FY2025	$6.2B	$625.0M	10.1%	$11.1B	35/100

Where Abbott Laboratories Ranks

Frequently Asked Questions

What is Abbott Laboratories's annual revenue?

Abbott Laboratories (ABT) reported $44.3B in total revenue for fiscal year 2025. This represents a 5.7% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.

How fast is Abbott Laboratories's revenue growing?

Abbott Laboratories (ABT) revenue grew by 5.7% year-over-year, from $42.0B to $44.3B in fiscal year 2025.

Is Abbott Laboratories profitable?

Yes, Abbott Laboratories (ABT) reported a net income of $6.5B in fiscal year 2025, with a net profit margin of 14.7%.

What is Abbott Laboratories's EBITDA?

Abbott Laboratories (ABT) had EBITDA of $11.2B in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.

How much debt does Abbott Laboratories have?

As of fiscal year 2025, Abbott Laboratories (ABT) had $8.5B in cash and equivalents against $9.9B in long-term debt.

What is Abbott Laboratories's gross margin?

Abbott Laboratories (ABT) had a gross margin of 56.4% in fiscal year 2025, indicating the percentage of revenue retained after direct costs of goods sold.

What is Abbott Laboratories's operating margin?

Abbott Laboratories (ABT) had an operating margin of 18.2% in fiscal year 2025, reflecting the profitability of core business operations before interest and taxes.

What is Abbott Laboratories's net profit margin?

Abbott Laboratories (ABT) had a net profit margin of 14.7% in fiscal year 2025, representing the share of revenue converted into profit after all expenses.

Does Abbott Laboratories pay dividends?

Yes, Abbott Laboratories (ABT) paid $2.40 per share in dividends during fiscal year 2025.

What is Abbott Laboratories's return on equity (ROE)?

Abbott Laboratories (ABT) has a return on equity of 12.5% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.

What is Abbott Laboratories's free cash flow?

Abbott Laboratories (ABT) generated $7.4B in free cash flow during fiscal year 2025. This represents a 16.4% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.

What is Abbott Laboratories's operating cash flow?

Abbott Laboratories (ABT) generated $9.6B in operating cash flow during fiscal year 2025, representing cash generated from core business activities.

What are Abbott Laboratories's total assets?

Abbott Laboratories (ABT) had $86.7B in total assets as of fiscal year 2025, including both current and long-term assets.

What are Abbott Laboratories's capital expenditures?

Abbott Laboratories (ABT) invested $2.2B in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.

How much does Abbott Laboratories spend on research and development?

Abbott Laboratories (ABT) invested $2.9B in research and development during fiscal year 2025.

Does Abbott Laboratories buy back shares?

Yes, Abbott Laboratories (ABT) spent $893.0M on share buybacks during fiscal year 2025, returning capital to shareholders by reducing shares outstanding.

How many shares does Abbott Laboratories have outstanding?

Abbott Laboratories (ABT) had 1.74B shares outstanding as of fiscal year 2025.

What is Abbott Laboratories's current ratio?

Abbott Laboratories (ABT) had a current ratio of 1.58 as of fiscal year 2025, which is generally considered healthy.

What is Abbott Laboratories's debt-to-equity ratio?

Abbott Laboratories (ABT) had a debt-to-equity ratio of 0.19 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.

What is Abbott Laboratories's return on assets (ROA)?

Abbott Laboratories (ABT) had a return on assets of 7.5% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.

What is Abbott Laboratories's P/E ratio?

Abbott Laboratories (ABT) trades at 26.9x earnings, its market capitalization divided by net income of $6.3B net income, trailing 12 months to March 31, 2026. The market capitalization is $168.7B as of Oct 2, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.

What is Abbott Laboratories's price-to-sales ratio?

Abbott Laboratories (ABT) trades at 3.7x sales, its market capitalization divided by revenue of $45.1B revenue, trailing 12 months to March 31, 2026. The market capitalization is $168.7B as of Oct 2, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.

What is Abbott Laboratories's Altman Z-Score?

Abbott Laboratories (ABT) has an Altman Z-Score of 4.68, placing it in the Safe Zone (low bankruptcy risk). The Z-Score combines five financial ratios (working capital, retained earnings, EBIT, market capitalization, and revenue relative to total assets) to predict the likelihood of bankruptcy. Scores above 2.99 indicate financial safety while scores below 1.81 suggest financial distress. Learn more in our complete guide to financial health indicators.

What is Abbott Laboratories's Piotroski F-Score?

Abbott Laboratories (ABT) has a Piotroski F-Score of 5 out of 9, indicating neutral financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.

Are Abbott Laboratories's earnings high quality?

Abbott Laboratories (ABT) has an earnings quality ratio of 1.47x, considered cash-backed (high quality). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.

Can Abbott Laboratories cover its interest payments?

Abbott Laboratories (ABT) has an interest coverage ratio of 16.33x, meaning it can comfortably cover its interest obligations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.

How financially healthy is Abbott Laboratories?

Abbott Laboratories (ABT) scores 69 out of 100 on our Financial Health Score, indicating strong standing within its operating companies peer group. The score is a 0-100 composite of six dimensions (Profitability, Growth, Leverage, Liquidity, Cash Flow, Returns), each ranked as a percentile relative to companies in the same scoring family (banks against banks, REITs against REITs, and so on) rather than across all industries. It rates the quality of the business, not whether the stock is fairly priced, and is not financial advice. Learn more in our complete guide to financial health indicators.